Clinical Trials Directory

Trials / Terminated

TerminatedNCT00692094

Blind Elderly Melatonin Treatment Study

Melatonin Entrainment of Elderly Blind Free-runners

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
12 (actual)
Sponsor
Oregon Health and Science University · Academic / Other
Sex
All
Age
55 Years
Healthy volunteers
Not accepted

Summary

The primary focus of this five-year study will be to optimize the melatonin dosing regimen for synchronizing the body clocks of elderly blind individuals to the 24-hour day.

Detailed description

The investigators intend to study as many as 26 subjects through up to four melatonin treatment regimens, all of which involve a dose step-down in which the melatonin dose will be reduced gradually to find the lowest effective dose. The 4 treatment plans differ only in the start dose and the time of administration. Successfully treated subjects will enter a one-year intensive assessment of the safety and efficacy of melatonin treatment in which the subject will take the same dose for one year and complete biweekly assessments of efficacy and side-effects. The final phase of the study involves a placebo discontinuation, in which the subject's circadian rhythm will be returned to the baseline rhythm (this may take up to 6 months for some subjects).

Conditions

Interventions

TypeNameDescription
BIOLOGICALMelatonin0.025 mg-0.5 mg, daily given at a time when it is expected to delay the timing of the body clock.
BIOLOGICALMelatonin0.025 mg - 0.5 mg, daily, at a time when melatonin should advance the timing of their body clock.
BIOLOGICALMelatonin0.025 mg - 10 mg, daily, at a time when melatonin should advance the timing of their body clock.
BIOLOGICALMelatonin0.025 mg - 20 mg, daily, at a time when the melatonin should advance the timing of the body clock.

Timeline

Start date
2004-08-01
Primary completion
2008-05-01
Completion
2008-12-01
First posted
2008-06-06
Last updated
2019-11-27
Results posted
2019-11-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00692094. Inclusion in this directory is not an endorsement.